Cleveland Alzheimers Disease Research Center

克利夫兰阿尔茨海默病研究中心

• 批准号: 10263707
• 负责人: JAMES Bruce LEVERENZ
• 金额: $ 309.02万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10263707
• 关键词: Address; African American; Aging; Alzheimer' s Disease; Alzheimer' s disease related dementia; Alzheimer' s disease risk; Autopsy; Behavioral; Biological Markers; Biology; Brain; Brain Diseases; Cessation of life; Clinic; Clinical; Clinical Research; Cognitive; Collaborations; Collection; Communities; Consent; Data; Data Analyses; Dementia; Dementia with Lewy Bodies; Development; Diagnosis; Disease; Disease Progression; Enrollment; Ensure; Evaluation; Financial Support; Fostering; Foundations; Freezing; Funding; Genetic; Genetic Risk; Goals; Heterogeneity; Human; Image; Impairment; Individual; Infrastructure; Institutes; Institution; International; Intervention; Laboratory Finding; Link; Magnetic Resonance Imaging; Medical center; Memory; Molecular; Monitor; Motor; National Institute on Aging; Ohio; Participant; Pathologic; Pathology; Persons; Phenotype; Physicians; Population; Research; Research Design; Research Personnel; Resources; Risk; Risk Factors; Scientist; Speed; Standardization; Structure; System; Therapeutic; Time; Tissue Sample; Tissues; Training; Translating; Translational Research; Translations; Underrepresented Populations; United States Department of Veterans Affairs; United States National Institutes of Health; Universities; University Hospitals; Veterans; amyloid imaging; base; career; career development; cell repository; cohort; collaborative environment; community center; data management; data repository; design; drug discovery; education research; ethnic minority population; health disparity; high risk; imaging biomarker; improved; individualized medicine; insight; mild cognitive impairment; neuroimaging; neuropathology; next generation; novel therapeutics; outreach; participant retention; patient engagement; precision medicine; programs; protective factors; racial minority; recruit; social stigma; statistics; success; targeted biomarker; therapeutic target; tool

PROJECT SUMMARY The Cleveland Alzheimer's Disease Research Center (CADRC) is a collaborative effort of physicians and investigators from Case Western Reserve University (CWRU), Cleveland Clinic Foundation (CCF), MetroHealth System (MHS), University Hospitals (UH), and the Louis Stokes Cleveland VA Medical Center (LSCVAMC), to foster excellence in research and facilitate discovery as an established National Institute on Aging (NIA) funded Alzheimer's Disease Research Center. The CADRC represents a rich clinical and research community and an estimated 220,000 Ohioans who suffer from Alzheimer's disease (AD) or AD-related dementias (ADRD). The CADRC has 8 Cores and a Research Education Component designed to create the foundation that will enhance the research efforts of the Northeast Ohio AD/ADRD research community, as well as add unique value to the national Alzheimer's Disease Research Centers (ADRC) program and other national and international research programs. The CADRC is focused on participants that will help us understand the pathobiology of clinical and pathological heterogeneity observed in dementia including atypical and amnestic AD, dementia with Lewy bodies, cognitively normal individuals with different levels of genetic risk for AD, and diversity of participant populations (Clinical and Outreach, Recruitment, and Engagement Cores). To support the CADRC goals, the focus will be on deep phenotyping of participants with longitudinal and systematic cognitive, behavioral and motor characterization (Clinical Core), genetic and biofluid biomarker collection and analysis (Biomarker Core), imaging (Neuroimaging Core), and autopsy after death (Neuropathology Core). Results will be shared with the research community in a timely and regular manner to allow other investigators to benefit from the CADRC efforts (Data Management and Statistics Core). In addition, the CADRC will train the next generation of investigators utilizing a rigorous and well-designed Research Education Component, support translation of new laboratory findings through the Translational Therapeutics Core, and support high risk/high gain projects through the developmental program as a part of the Administrative Core. The ultimate goals are to advance the precision medicine approach to dementia diagnosis and treatment, support the development of early stage investigators, assist all stages of investigators with tools for performing human-based research, and better engage underrepresented populations in AD/ADRD research.

项目摘要 克利夫兰阿尔茨海默病研究中心（CADRC）是一个由医生们共同努力的机构， 来自凯斯西储大学（CWRU），克利夫兰临床基金会（CCF）， MetroHealth System（MHS）、大学医院（UH）和Louis Stokes Cleveland VA医疗中心 （LSCVAMC），以促进卓越的研究和促进发现作为一个既定的国家研究所， 老龄化（NIA）资助阿尔茨海默病研究中心。CADRC代表了丰富的临床和研究 社区和估计220，000患有阿尔茨海默病（AD）或AD相关疾病的俄亥俄州人 痴呆症（ADRD）。CADRC有8个核心和一个研究教育组件，旨在创建 该基金会将加强东北俄亥俄州AD/ADRD研究社区的研究工作，以及 为国家阿尔茨海默病研究中心（ADRC）计划和其他项目增加了独特的价值。 国家和国际研究计划。CADRC专注于帮助我们的参与者 了解在痴呆症中观察到的临床和病理异质性的病理生物学，包括非典型性 和遗忘型AD、路易体痴呆、认知正常个体与不同水平的遗传风险 以及参与者人群的多样性（临床和外展，招募和参与核心）。 为了支持CADRC的目标，重点将放在参与者的纵向和 系统性认知、行为和运动表征（临床核心）、遗传和生物流体生物标志物 收集和分析（生物标志物核心）、成像（神经成像核心）和死后尸检 （神经病理学核心）。研究结果将及时和定期与研究界分享， 允许其他研究者从CADRC工作中受益（数据管理和统计核心）。在 此外，CADRC将利用严格和精心设计的 研究教育部分，通过翻译支持新的实验室发现的翻译 治疗核心，并通过发展计划支持高风险/高收益项目，作为 行政核心。最终目标是推进痴呆症的精准医学方法 诊断和治疗，支持早期研究者的发展，协助所有阶段的研究者 使用工具进行以人为本的研究，并更好地让代表性不足的人群参与 AD/ADRD研究。